Follow us

History of NHT

Filters :

2005

Invention of AGuIX®

2007

Discovery of radio-sensitization effect of AGuIX® in combination with radiotherapy

2011

Princeps patent on AGuIX®

2015

Production of the first batch of human injectable drug manufactured by CARBOGEN AMCIS

2015

2015/2016 Inception of NHT by four co-founders Géraldine Le Duc, Olivier Tillement, François Lux, Sandrine Dufort

2015

Research collaboration with Institut Lumière Matière

2016

Prizes « Tremplin Entreprises » Sénat -ESSEC & « Coup de Cœur » France Biotech

2016

Prize R2B Onco Cancéropole Lyon

2016

First-in-human injection of AGuIX® in the frame of NANORAD Phase 1 clinical trial on brain metastases at CHU Grenoble Alpes

2017

First Patent with Harvard Medical School

2017

Creation of Chemistry Manufacturing and Control unit (arrival of Tristan Doussineau) and beginning of partnership with SANOFI for API manufacturing

2017

Research collaboration with Institut Gustave Roussy

2017

Start of NANOCOL Phase 1 clinical trial on cervical cancer at Institut Gustave Roussy

2018

Prize “Business with Attitude” awarded to Géraldine Le Duc CEO (Entreprenariat féminin, Figaro Madame)

2018

Production of the second batch of human injectable drug manufactured by CARBOGEN AMCIS

2018

Review article on AGuIX® by François Lux et al. in The British Journal of Radiology

2018

Prize IMPI awarded to ILM – Fennec Team (Olivier Tillement)

2019

Prize Galien (MedStartUp) (New York) – Third prize for the “Best collaboration in the pharmaceutical or biotechnology industry in 2019” related to the collaboration with Dana Farber Cancer Institute

2019

Series A funding (13M€) – BPI Innobio2, Arbevel, Omnes, Supernova

2019

Appointment of Hervé Brailly as Chairman of the Supervisory Board

2019

Creation of Administrative & Financial unit (arrival of Caroline Cayre and Florence Cruz)

2019

Final report of NANORAD Phase 1 clinical trial and start of NANORAD 2 multicentric Phase 2 clinical trial

2020

Structuration of the Clinical Development unit – Recruitment of Markus Loeffler as Chief Medical Officer and Khalide Seddik as Clinical Operations Responsible

2020

Production of the third batch of human injectable drug manufactured by SANOFI/CARBOGEN AMCIS

2020

First publication about the First-In-Human trial NANORAD in Science Advances

2020

Publication on the radiosensitization mechanism of AGuIX®

2020

October – Investigational New Drug (IND) becomes active

2020

Second patent with Harvard Medical School (MRI-Linac) and Grant NIH $3M related to the collaboration with Harvard Medical School

2020

Leverage of €6M of non dilutive funds performed including bank loans, BPI subsidies and academic grant (NIH, ANR)

2020

Arrival of Michel Julien as Head of Chemistry Manufacturing and Control

2021

Internalization of MRI Data analysis knowledge and know how (arrival of Fabien Boux as MRI Engineer and support from Yannick Crémillieux as MRI expert)

2021

February – Obtainment of the ODD from the US FDA for the treatment of pancreatic cancer with AGuIX®

2021

April – Second publication about the First-In-Human trial NANORAD in Radiotherapy & Oncology

2021

May – Obtainment of the ODD from the US FDA for the treatment of glioblastoma with AGuIX®

2021

Production of the fourth batch of human injectable drug manufactured by SANOFI/CARBOGEN AMCIS

2021

October – First patients enrolled in NanoBrainMets and NanoSmart clinical trials at Dana-Farber Brigham Cancer Center, Boston (USA)